If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

IHH-LITIGATION-DAIICHI-SANKYO:IHH Healthcare’s damages against Daiichi could reach $1.25 billion, expert report says (Feb 6) ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

IHH Healthcare's Singaporean subsidiary, Northern TK Venture, has raised its damage claim against Japan's Daiichi Sankyo in a Tokyo court to JPY 199.8 billion amid a legal battle over a stalled open ...

IHH Healthcare said on Thursday its unit has sought up to 109.3 billion rupees ($1.25 billion) in compensation from Japan's ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

Learn more about whether Ultragenyx Pharmaceutical Inc. or Vericel Corporation is a better investment based on AAII's A+ ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...